Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Gains from Sales and Divestitures (2017 - 2024)

Historic Gains from Sales and Divestitures for Coherus Oncology (CHRS) over the last 11 years, with Q4 2024 value amounting to $2.8 million.

  • Coherus Oncology's Gains from Sales and Divestitures rose 11809.85% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year increase of 11809.85%. This contributed to the annual value of $2.8 million for FY2024, which is 11809.85% up from last year.
  • As of Q4 2024, Coherus Oncology's Gains from Sales and Divestitures stood at $2.8 million, which was up 11809.85% from $1.3 million recorded in Q4 2023.
  • Over the past 5 years, Coherus Oncology's Gains from Sales and Divestitures peaked at $2.8 million during Q4 2024, and registered a low of $223767.0 during Q4 2020.
  • For the 5-year period, Coherus Oncology's Gains from Sales and Divestitures averaged around $1.1 million, with its median value being $806854.0 (2022).
  • As far as peak fluctuations go, Coherus Oncology's Gains from Sales and Divestitures soared by 416.54% in 2020, and later soared by 11809.85% in 2024.
  • Over the past 5 years, Coherus Oncology's Gains from Sales and Divestitures (Quarter) stood at $223767.0 in 2020, then skyrocketed by 108.22% to $465930.0 in 2021, then soared by 73.17% to $806854.0 in 2022, then skyrocketed by 58.75% to $1.3 million in 2023, then surged by 118.1% to $2.8 million in 2024.
  • Its Gains from Sales and Divestitures was $2.8 million in Q4 2024, compared to $1.3 million in Q4 2023 and $806854.0 in Q4 2022.